News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
116 Results
Type
Article (15)
Company Profile (1)
Press Release (100)
Section
Business (43)
Deals (4)
Drug Development (18)
FDA (2)
Job Trends (13)
News (63)
Policy (5)
Tag
Alliances (1)
Approvals (1)
Best Places to Work (15)
Biotechnology (1)
Breast cancer (1)
Cancer (1)
Clinical research (17)
Compensation (2)
C-suite (1)
Data (4)
Duchenne muscular dystrophy (5)
Earnings (16)
Events (24)
Executive appointments (3)
FDA (1)
GLP-1 (1)
Healthcare (7)
IPO (4)
NextGen: Class of 2026 (1)
Non-profit (1)
Patents (1)
People (39)
Phase 1 (12)
Phase 2 (7)
Phase 3 (1)
Pipeline (4)
Preclinical (2)
Regulatory (6)
Startups (1)
Date
Last 365 days (25)
2025 (25)
2024 (23)
2023 (22)
2022 (22)
2021 (19)
2020 (2)
2019 (1)
Location
Asia (1)
Delaware (1)
Europe (12)
Massachusetts (32)
United States (33)
116 Results for "pepgen".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer
December 9, 2025
·
2 min read
Press Releases
PepGen to Participate in Upcoming November 2025 Investor Conferences
November 4, 2025
·
1 min read
Press Releases
PepGen Announces Proposed Public Offering
September 25, 2025
·
3 min read
Press Releases
PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
November 13, 2025
·
10 min read
Press Releases
PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule
November 13, 2025
·
5 min read
Press Releases
PepGen Announces Pricing of $100 Million Public Offering
September 24, 2025
·
3 min read
Press Releases
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer
December 10, 2025
·
2 min read
Press Releases
PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients
September 24, 2025
·
10 min read
Press Releases
PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society
October 2, 2025
·
2 min read
Duchenne Muscular Dystrophy
Déjà Vu for PepGen as FDA Places Hold on DMD Drug
The FDA has put a stop to U.S. initiation of PepGen’s Phase II trial for its Duchene muscular dystrophy treatment. The company faced the same hurdle for an earlier neuromuscular candidiate in 2023.
December 16, 2024
·
2 min read
·
Annalee Armstrong
1 of 12
Next
